Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs ServiceNow Inc (NOW) Price & Performance

Cassava Sciences IncTrade
ServiceNow IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs ServiceNow Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while ServiceNow Inc trades at $126.75 (market cap $129.11B). The key difference: ServiceNow Inc is far larger — about 2703.9× Cassava Sciences Inc's market cap, and ServiceNow Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNANOW
Market Cap
$47.75M$129.11B
Sector
HealthTechnology
52-Week High
$4.64$192.23
52-Week Low
$0.87$83.00
Enterprise Value
-$34.93M$132.90B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

ServiceNow Inc

ServiceNow (NOW) trades at $127.54, up 2.13% with strong technical momentum. The stock shows robust fundamentals with 2025 revenue reaching $13.28B and net income of $1.75B, though valuation ratios remain elevated (P/E 78.05). Recent earnings performance has been mixed with Q2 2026 beating expectations but Q1 missing. Technical indicators show bullish moving averages but overbought RSI signals. The company maintains strong analyst support with 87% buy ratings and a $138.26 consensus target.

ServiceNow presents a compelling growth story with AI-driven expansion opportunities, though premium valuation requires careful risk assessment. Key risks include competitive pressures in enterprise software and execution challenges in maintaining high growth rates. The stock's current technical overbought condition suggests potential near-term consolidation before further upside potential toward analyst targets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About ServiceNow Inc

ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).

Read more on NOW